We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.44%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$553M
AUM Growth
+$22M
Cap. Flow
-$5.91M
Cap. Flow %
-1.07%
Top 10 Hldgs %
30.71%
Holding
131
New
7
Increased
28
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.16M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$4.22M
3
AKRX
Akorn Inc
AKRX
+$3.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.21M
5
ENDP
Endo International plc
ENDP
+$2.74M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$6.62M
2
CAH icon
Cardinal Health
CAH
+$6.02M
3
MDVN
MEDIVATION, INC.
MDVN
+$4.7M
4
STJ
St Jude Medical
STJ
+$4.68M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 92.11%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
1
Medtronic
MDT
$106B
$21.4M 3.86%
247,500
-35,000
-12% -$3.05M
SYK icon
2
Stryker
SYK
$123B
$21M 3.8%
180,800
+3,800
+2% +$443K
CELG
3
DELISTED
Celgene Corp
CELG
$20.3M 3.67%
194,250
-1,800
-0.9% -$195K
ILMN icon
4
Illumina
ILMN
$28.2B
$17.2M 3.1%
97,120
+2,981
+3% +$477K
BIIB icon
5
Biogen
BIIB
$30.4B
$17.1M 3.08%
54,500
– –
ABT icon
6
Abbott
ABT
$175B
$16.2M 2.93%
384,000
+2,500
+0.7% +$107K
REGN icon
7
Regeneron Pharmaceuticals
REGN
$70.9B
$15.3M 2.76%
38,000
+8,000
+27% +$3.21M
AMGN icon
8
Amgen
AMGN
$198B
$13.9M 2.52%
83,500
– –
UNH icon
9
UnitedHealth
UNH
$387B
$13.9M 2.51%
99,200
– –
BSX icon
10
Boston Scientific
BSX
$65.4B
$13.7M 2.47%
575,000
+75,000
+15% +$1.79M
GILD icon
11
Gilead Sciences
GILD
$167B
$12.4M 2.24%
156,500
– –
LGND icon
12
Ligand Pharmaceuticals
LGND
$6.08B
$10.9M 1.97%
171,329
+57,468
+50% +$4.22M
ZBH icon
13
Zimmer Biomet
ZBH
$17.6B
$10.4M 1.88%
82,400
-6,386
-7% -$789K
EW icon
14
Edwards Lifesciences
EW
$49.4B
$10.2M 1.85%
255,000
+51,000
+25% +$1.92M
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$15.5B
$10.2M 1.84%
83,800
+8,500
+11% +$1.15M
BDX icon
16
Becton Dickinson
BDX
$43.6B
$9.88M 1.79%
56,375
-4,100
-7% -$701K
CNC icon
17
Centene
CNC
$32.8B
$9.47M 1.71%
282,860
+48,100
+20% +$1.67M
HOLX
18
DELISTED
Hologic
HOLX
$9.4M 1.7%
242,100
+3,800
+2% +$143K
BAX icon
19
Baxter International
BAX
$11.7B
$9.04M 1.63%
190,000
+24,000
+14% +$1.13M
VTRS icon
20
Viatris
VTRS
$20.1B
$8.98M 1.62%
235,700
+116,000
+97% +$5.16M
CAH icon
21
Cardinal Health
CAH
$53.5B
$8.88M 1.6%
114,280
-74,500
-39% -$6.02M
ISRG icon
22
Intuitive Surgical
ISRG
$122B
$8.7M 1.57%
108,000
– –
TEVA icon
23
Teva Pharmaceuticals
TEVA
$37.3B
$8.61M 1.56%
187,190
-42,000
-18% -$2.19M
INCY icon
24
Incyte
INCY
$23.4B
$8.58M 1.55%
91,000
– –
CI icon
25
Cigna
CI
$74.5B
$7.78M 1.41%
59,722
+11,722
+24% +$1.53M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2016 Portfolio in Review

As of Q3 2016, Bellevue Group held 131 positions worth $553M, up 4.1% from $531M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group's Q3 2016 filing shows 7 new, 28 increased, 30 reduced and 10 closed positions. Its largest new stake was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M. The largest sale was CVS Health, an estimated $6.62M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials.

  • Bellevue Group's largest Q3 2016 buy was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M.
  • Bellevue Group added most to Viatris in Q3 2016, an estimated $5.16M increase.
  • Bellevue Group's biggest Q3 2016 reduction was CVS Health, cutting an estimated $6.62M.
  • Bellevue Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $4.7M.
  • Bellevue Group's ten largest holdings make up 31% of its $553M portfolio in Q3 2016.
  • Bellevue Group opened 7 new positions and closed 10 in Q3 2016.
  • Bellevue Group's portfolio value rose 4.1% quarter-over-quarter to $553M.

Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.